LG Chem Receives the Korean MFDS’ Approval for Xelenka for the Treatment of Autoimmune Disease
Shots:
- The company received marketing authorization from the Korean Ministry of Food and Drug Safety for Xelenka (biosimilar to Humira) for the treatment of autoimmune disorders
- LG Chem filed the marketing application with MFDS in Dec 2022. Moreover, this approved is granted for the high concentration of humira which is citrate free
- Xelenka like Humira is an Anti-TNF mAb indicated for RA, PA, Uveitis in adults, CD & JIA in children and this a second approval for LG Chem for autoimmune diseases after approval of biosimilar Eucept
Ref: Korea BioMed | Image: LG Chem
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
